secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001493152-23-039900
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q3 net loss $3.2M ($0.29/shr); cash $44.9M; LP-284 IND cleared, LP-184 dosed first patient
--------------------------------------------------------------------------------

- Net loss $3.2M ($0.29/shr) vs $2.3M ($0.21/shr) in Q3 2022; R&D rose to $2.2M from $0.7M due to prior-year one-time payment.
- Cash, equivalents, and marketable securities $44.9M at Sep 30 vs $55.2M at Dec 31; runway into at least Q3 2025.
- Received FDA IND clearance for LP-284 Phase 1 trial in refractory non-Hodgkin's lymphomas; dosed first patient in LP-184 Phase 1 solid tumor basket trial.
- RADR AI platform surpassed 36B oncology datapoints; new modules for ADC design, BBB permeability prediction, and IO combination therapy.
- Phase 2 Harmonic trial of LP-300 in never-smoker NSCLC expanded to additional U.S. sites and Asia; Dr. Joseph Treat named lead PI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315223039900/0001493152-23-039900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315223039900/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer